Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Information

v3.25.2
Segment Information
12 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Information

Note 13. Segment Information

 

The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company’s singular focus is the development of treatments for cannabis toxicity, such as unintentional cannabis poisoning, ACI, and the broader landscape of acute cannabis-induced conditions. The Company’s chief operating decision maker (“CODM”) is the Chief Executive Officer.

 

The CODM manages and allocates resources to the operations of the Company on a total company basis and segment performance is evaluated based on net loss. The Company’s CEO uses financial information for purposes of evaluating performance, understanding future forecasted results and allocating resources. The measure of segment assets is reported on the balance sheet as total assets. All of the Company’s tangible assets are held in the United States.

 

The following table presents selected financial information with respect to the Company’s single operating segment and its significant segment expenses for the years ended June 30, 2025 and 2024:

 

         
    June 30,  
    2025     2024  
Pre-clinical and clinical studies   $ 1,842,209     $ 1,668,780  
Contract manufacturing     1,196,728       795,134  
Consultants and other research and development     1,261,004       1,085,023  
Compensation and related benefits     1,403,200       1,733,032  
Professional and consultant fees     1,291,557       1,526,442  
Stock-based compensation expense     1,446,824       758,884  
Directors’ and officers’ insurance     497,748       469,855  
Facilities, fees and other related costs     284,211       271,605  
Interest expense     382,014       151,230  
Interest income     (257,913 )     (249,022 )
Grant income     (864,014 )     -  
Other     1,195       (9,260 )
 Net loss   $ (8,484,763 )   $ (8,201,703 )